Rapidly Progressive Gait and Coordination Difficulties

2021 ◽  
pp. 111-112
Author(s):  
Andrew McKeon

A 59-year-old woman noted sudden onset of slurred speech. Within a few days, she noted double vision, gait unsteadiness, and incoordination of her limbs. She sought care at her local emergency department. Computed tomography and magnetic resonance imaging of the head were negative for stroke. Her symptoms persisted. Neurologic examination indicated a moderate pancerebellar ataxia, without additional abnormalities. Her pursuit eye movements were saccadic. She had binocular diplopia with horizontal, gaze-evoked nystagmus. She had ataxic dysarthria and dysmetria of all limbs. Her steps and walking were irregular and she could not accomplish tandem gait. Additional neural antibody testing was undertaken, beyond the classic paraneoplastic antibodies. Metabotropic glutamate receptor 1-immunoglobulin G was detected in the serum and cerebrospinal fluid. The patient was diagnosed with autoimmune cerebellar ataxia. Because of the reported association of metabotropic glutamate receptor 1-immunoglobulin G with Hodgkin disease and non-Hodgkin lymphoma, positron emission tomography–computed tomography of the trunk (orbits to thighs) was performed, which was negative. After 6 weeks of intravenous methylprednisolone, the patient returned for evaluation. She had a mild ataxic dysarthria and minimal dysmetria of her left upper extremity only. She could tandem walk almost without error, and her gait appeared normal (no longer broad-based). At that point, immunotherapy was discontinued. At last follow-up, her neurologic examination findings remained stable. The subacute onset and rapid progression of ataxic symptoms in this adult patient led to suspicion for an autoimmune cause.

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anna E. M. Bastiaansen ◽  
A. Mieke Timmermans ◽  
Marcel Smid ◽  
Carolien H. M. van Deurzen ◽  
Esther S. P. Hulsenboom ◽  
...  

AbstractNew therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate receptor 1 (mGluR1) is suggested as a potential new molecular target. We examined the prevalence mGluR1 expression in different clinically relevant breast cancer subgroups and determined its association with prognosis. In this retrospective cohort, 394 consecutive primary breast cancer tissues were incorporated into a tissue microarray and immunohistochemically stained for mGluR1. The prevalence of mGluR1 protein expression in different breast cancer subgroups was evaluated and correlated with metastasis-free survival (MFS) and overall survival (OS). In total, 56% (n = 219) breast cancer tissues had mGluR1 expression. In estrogen receptor (ER)-negative tumors, 31% (n = 18/58) had mGluR1 expression that was significantly associated with MFS (HR 5.00, 95% CI 1.03–24.35, p = 0.046) in multivariate analysis, independently from other prognostic factors. Of the 44 triple-negative breast cancer (TNBC), 25% (n = 11) expressed mGluR1. mGluR1 expression in TNBC was significantly associated with shorter MFS (HR 8.60, 95% CI 1.06–20.39, p = 0.044) and with poor OS (HR 16.07, 95% CI 1.16–223.10, p = 0.039). In conclusion, mGluR1 is frequently expressed in breast cancer. In ER-negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, especially for the more aggressive TNBC.


2012 ◽  
Vol 91 (3) ◽  
pp. 553-564 ◽  
Author(s):  
Velina Guergueltcheva ◽  
Dimitar N. Azmanov ◽  
Dora Angelicheva ◽  
Katherine R. Smith ◽  
Teodora Chamova ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e81126 ◽  
Author(s):  
Malathi Banda ◽  
Cecilia L. Speyer ◽  
Sara N. Semma ◽  
Kingsley O. Osuala ◽  
Nicole Kounalakis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document